General Background
Founded in 2002, Catalyst Pharmaceuticals (CPRX) specializes in obtaining treatments for rare diseases, many of which have no FDA-approved treatment options. Much of this article focuses on the current status of the company, with particular emphasis on the many catalysts for this upcoming year. There are also many references to important statements made by management during the November, 13, 2019 conference call. Overall, with the stock trading at $4.50-4.75 and with the company projected to become profitable this year, Catalyst is likely a great value play. Cantor Fitzgerald has a price